A predictive model for chemotherapy-related diminished ovarian reserve in reproductive-age women

Age, cancer type, type of chemotherapy, and pre-chemotherapy serum AMH level can accurately predict diminished ovarian reserve caused by chemotherapy.

VOLUME 115, ISSUE 2, P431-437


Margaret M. Hopeman, M.D., Katherine E. Cameron, M.D., M.B.E., Maureen Prewitt, R.N., C.C.E., Kurt Barnhart, M.D., M.S.C.E., Jill P. Ginsberg, M.D., Mary D. Sammel, Sc.D., Clarisa R. Gracia, M.D., M.S.C.E.



To develop and internally validate a clinical predictive tool to assess the likelihood that a young cancer patient will experience diminished ovarian reserve (DOR) after chemotherapy.


Prospective cohort study.


University hospitals.


Postpubertal adolescent and young adult women with a new diagnosis of cancer requiring chemotherapy.



Main Outcome Measure(s)

Diminished ovarian reserve after completion of and recovery from chemotherapy, defined as serum antimüllerian hormone (AMH) <1 ng/mL at 8–24 months after completion of chemotherapy.


A multivariable logistic regression model which includes age, cancer type, exposure to an alkylating agent, and baseline AMH value accurately predicts the diagnosis of DOR after chemotherapy with an area under the receiver operating characteristic curve of 0.89.


Pretreatment information on age, cancer type, use of an alkylating agent, and baseline AMH levels make up a clinically useful predictive tool to identify which women are most at risk for DOR caused by chemotherapy.